Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials

作者全名："Wu, Jiangfan; Zhao, Xiaofang; Chen, Huanhuan; Zhu, Shenyin"

作者地址："[Wu, Jiangfan; Zhao, Xiaofang; Chen, Huanhuan; Zhu, Shenyin] Chongqing Med Univ, Affiliated Hosp 1, Dept Pharm, 1 Youyi Rd, Chongqing 400016, Peoples R China; [Wu, Jiangfan; Zhao, Xiaofang; Chen, Huanhuan] Chongqing Med Univ, Sch Pharm, Chongqing, Peoples R China"

通信作者："Zhu, SY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Pharm, 1 Youyi Rd, Chongqing 400016, Peoples R China."

来源：JOURNAL OF DIABETES AND ITS COMPLICATIONS

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000931965400004

JCR分区：Q3

影响因子：3

年份：2022

卷号：36

期号：12

开始页：　

结束页：　

文献类型：Article

关键词：Sotagliflozin; Antidiabetic drug; SGLT 1/2 inhibitor; Meta-analysis; Metabolic benefit

摘要："Aim: To update the meta-analysis of the metabolic effects of a dual sodium-glucose co-transpoter-1/2 inhibitor, sotagliflozin, on blood pressure (BP) and body weight in people with diabetes. Methods: An electronic search up to March 8, 2022, were conducted to determine eligible randomized-controlled trials of sotagliflozin-reporting BP and weight change outcomes in adults with diabetes. Results: 16 trials were included, with a combined cohort of 19,140 patients. Compared with placebo, sotagliflozin had a mean systolic blood pressure reduction (weighted mean differences (WMDs) -2.60 mmHg, 95 % CI: -2.90 to -2.30), mean diastolic blood pressure reduction (WMD -0.96 mmHg, 95 % CI: -1.17 to -0.75), and mean weight loss (WMD -1.88 kg, 95 % CI: -2.16 to -1.59). Metabolic effects on BP-lowering and weight loss were observed across diabetes status, duration of follow-up, and chronic kidney disease comorbidity. Meanwhile sotagliflozin presented significant effects on people with type 1 diabetes and showed a dose-response relationship for BP-lowering and weight loss. Conclusion: This meta-analysis enriches the evidence on the metabolic benefits, including BP-lowering and weight loss, of sotagliflozin, and provide a reasonable therapeutic option for managing diabetes with metabolic syndrome. Further studies will be required to elucidate its long-term effects and role in metabolic syndrome management."

基金机构：　

基金资助正文：